文献速递泌尿生殖MR

前列腺直接MRI引导活检对临床管理的影响

Impact of Direct MRI-Guided Biopsy of the Prostate on Clinical Management.
PubMed 文献 · AJR Am J Roentgenol · 2019-04-01

回顾性纳入127例在多参数MRI发现PI-RADS 4或5类靶病灶后行直接MRI引导前列腺活检的患者,93例(73%)活检阳性,其中84例(90%)Gleason评分≥7;90例(71%)获得新诊断或诊断升级,其中57例(63%)接受根治性治疗。作者认为直接MRI引导活检在常见临床场景中与高比例显著前列腺癌检出及后续根治性治疗相关,应被视为适当情况下的重要补充诊断工具。

要点

  • MRI引导活检阳性率73%(93/127),其中Gleason评分≥7者占90%(84/93)。
  • 既往经直肠超声引导活检阴性者阳性率66%(57/86),活检初治者83%(10/12),主动监测者90%(26/29)。
  • 71%(90/127)获得新诊断或诊断升级,其中63%(57/90)接受前列腺切除、放疗或雄激素剥夺治疗。

核心结论

  • 直接MRI引导活检在常见临床场景中与高比例显著前列腺癌检出及后续根治性治疗相关,作者认为应被视为适当情况下的重要补充诊断工具。

研究设计与样本

  • 回顾性研究,纳入2013年8月至2018年1月在本机构行直接MRI引导前列腺活检的127例患者,其中未知诊断98例、未治疗且Gleason评分6分的前列腺癌29例。
  • 初始多参数直肠内线圈MRI显示一个或多个PI-RADS或PI-RADSv2 4类或5类靶病灶。
  • 复习所有可用医疗和影像记录以确定相关临床细节、活检结果及活检后管理。

诊断标准与关键数值

  • MRI引导活检阳性93/127(73%),其中Gleason评分≥7分者84/93(90%)。
  • 按临床场景分层,既往一次或多次经直肠超声引导活检阴性者阳性率66%(57/86),活检初治者83%(10/12),主动监测者90%(26/29)。
  • 总体90/127(71%)获得新诊断(67例)或诊断升级(23例),其中57/90(63%)接受前列腺切除、放疗或雄激素剥夺治疗。

临床应用与阅片要点

  • 对多参数MRI显示PI-RADS 4或5类靶病灶的患者,直接MRI引导活检可检出高比例显著前列腺癌。
  • 在既往经直肠超声引导活检阴性、活检初治及主动监测等常见临床场景中均可考虑直接MRI引导活检,作者认为其应被视为适当情况下的重要补充诊断工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study is to investigate the impact of direct MRI-guided biopsy of the prostate on clinical management in practice. MATERIALS AND METHODS. We retrospectively identified 127 patients with unknown (n = 98) or untreated prostate cancer with a Gleason score of 6 (n = 29) who underwent direct MRI-guided biopsy of the prostate at our institution between August 2013 and January 2018, after initial multiparametric endorectal MRI examination revealed one or more Prostate Imaging Reporting and Data System (PI-RADS or PI-RADSv2) category 4 or 5 target lesion. All available medical and imaging records were reviewed to determine pertinent clinical details, biopsy findings, and postbiopsy management. RESULTS. The mean patient age was 68 years (interquartile range, 63-73 years). Findings from MRI-guided biopsy were positive for 93 of 127 patients (73%), with prostate cancer of Gleason score of 7 or higher diagnosed in 84 of these 93 patients (90%). When stratified by clinical scenario, the rate of positive biopsy findings was 66% (57/86) for patients who had negative findings from one or more prior transrectal ultrasound-guided biopsies, 83% (10/12) for biopsy-naive patients, and 90% (26/29) for patients undergoing active surveillance. Overall, 90 of 127 patients (71%) received a new (n = 67) or upgraded (n = 23) diagnosis of prostate cancer, and 57 of these 90 patients (63%) proceeded to receive treatment with prostatectomy, radiation, or androgen deprivation therapy. CONCLUSION. The results of this study suggest that direct MRI-guided biopsy is associated with high rates of significant prostate cancer detection and subsequent definitive treatment across common clinical scenarios and should be considered an important supplementary diagnostic tool in the appropriate setting.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Meermeier NP, Foster BR, Liu JJ, et al. Impact of Direct MRI-Guided Biopsy of the Prostate on Clinical Management. AJR Am J Roentgenol. 2019. PMID: 30933652. doi:10.2214/AJR.18.21009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。